GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Mangoceuticals Inc (NAS:MGRX) » Definitions » Cash-to-Debt

Mangoceuticals (Mangoceuticals) Cash-to-Debt : 0.08 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mangoceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Mangoceuticals's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.08.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Mangoceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Mangoceuticals's Cash-to-Debt or its related term are showing as below:

MGRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08   Med: 7.16   Max: 18.77
Current: 0.08

During the past 3 years, Mangoceuticals's highest Cash to Debt Ratio was 18.77. The lowest was 0.08. And the median was 7.16.

MGRX's Cash-to-Debt is ranked worse than
83.26% of 657 companies
in the Healthcare Providers & Services industry
Industry Median: 0.64 vs MGRX: 0.08

Mangoceuticals Cash-to-Debt Historical Data

The historical data trend for Mangoceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mangoceuticals Cash-to-Debt Chart

Mangoceuticals Annual Data
Trend Dec21 Dec22 Dec23
Cash-to-Debt
0.59 1.94 5.73

Mangoceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.53 18.77 8.59 5.73 0.08

Competitive Comparison of Mangoceuticals's Cash-to-Debt

For the Health Information Services subindustry, Mangoceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mangoceuticals's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Mangoceuticals's Cash-to-Debt falls into.



Mangoceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Mangoceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Mangoceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mangoceuticals  (NAS:MGRX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Mangoceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Mangoceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Mangoceuticals (Mangoceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15110 N. Dallas Parkway, Suite 600, Dallas, TX, USA, 75248
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED product.
Executives
Amanda Elizabeth Hammer officer: Chief Operating Officer 5128 GADSDEN AVENUE, KELLER TX 76244
Jacob D. Cohen director, 10 percent owner, officer: CEO 2101 GLENDALE DRIVE, PLANO TX 75023
Tiger Cub Trust 10 percent owner 19 RYDDINGTON PL, DALLAS TX 75230
Kenny Myers director 5101 ADDISON CIRCLE,, UNIT 401,, ADDISON TX 75001
Lorraine Pamela D'alessio director 8200 WILSHIRE BLVD, BEVERLY HILLS, CALIFORNIA CA 90211
Eugene M Johnston officer: CFO PO BOX 669047, CHARLOTTE NC 28266
Jonathan Arango director, officer: President, COO and Secretary 15110 DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Alex P. Hamilton director 26 LOOP ROAD, BEDFORD NY 10506

Mangoceuticals (Mangoceuticals) Headlines